TY - JOUR
T1 - Transcatheter Therapies for Treating Tricuspid Regurgitation
AU - Rodés-Cabau, Josep
AU - Hahn, Rebecca T.
AU - Latib, Azeem
AU - Laule, Michael
AU - Lauten, Alexander
AU - Maisano, Francesco
AU - Schofer, Joachim
AU - Campelo-Parada, Francisco
AU - Puri, Rishi
AU - Vahanian, Alec
N1 - Funding Information:
Dr. Rodés-Cabau has received research grants from Edwards Lifesciences. Dr. Latib is a consultant for Medtronic, Direct Flow Medical, 4-Tech Cardio, and Mitralign. Dr. Laule has received a research grant and proctor fee from Edwards Lifesciences. Dr. Lauten is a consultant for St. Jude Medical, Medtronic, and P&F. Dr. Maisano is a consultant for Abbott Vascular, Medtronic, Valtech, and St. Jude Medical; has received grants from Abbott Vascular; has received royalties from Edwards Lifesciences; and is a co-founder of 4Tech Cardio. Dr. Vahanian is a consultant for Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this article to disclose. Ted Feldman, MD, served as Guest Editor for this paper.
Publisher Copyright:
© 2016 American College of Cardiology Foundation.
PY - 2016/4/19
Y1 - 2016/4/19
N2 - Tricuspid valve (TV) disease has been relatively neglected, despite the known association between severe tricuspid regurgitation (TR) and mortality. Few patients undergo isolated tricuspid surgery, which remains associated with high in-hospital mortality rates, particularly in patients with prior left-sided valve surgery. Patients with severe TR are often managed medically for years before TV repair or replacement. Current guidelines recommend TV repair in the presence of a dilated tricuspid annulus at the time of a left-sided valve surgical intervention, even if regurgitation is mild. This proposed algorithm aims to prevent the inevitable progression to severe TR and the need for a second surgical intervention. Recently, novel transcatheter treatment options were developed for treating patients with severe TR and right heart failure with prohibitive surgical risk. Here we describe currently available transcatheter treatment options for severe TR implanted at different levels: the junction between vena cavae and right atrium; the tricuspid annulus; or between TV leaflets, improving coaptation.
AB - Tricuspid valve (TV) disease has been relatively neglected, despite the known association between severe tricuspid regurgitation (TR) and mortality. Few patients undergo isolated tricuspid surgery, which remains associated with high in-hospital mortality rates, particularly in patients with prior left-sided valve surgery. Patients with severe TR are often managed medically for years before TV repair or replacement. Current guidelines recommend TV repair in the presence of a dilated tricuspid annulus at the time of a left-sided valve surgical intervention, even if regurgitation is mild. This proposed algorithm aims to prevent the inevitable progression to severe TR and the need for a second surgical intervention. Recently, novel transcatheter treatment options were developed for treating patients with severe TR and right heart failure with prohibitive surgical risk. Here we describe currently available transcatheter treatment options for severe TR implanted at different levels: the junction between vena cavae and right atrium; the tricuspid annulus; or between TV leaflets, improving coaptation.
KW - cardiac catheterization
KW - echocardiography
KW - pulmonary hypertension
KW - right ventricular dysfunction
KW - tricuspid valve
KW - tricuspid valve insufficiency
UR - http://www.scopus.com/inward/record.url?scp=84963644389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963644389&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2016.01.063
DO - 10.1016/j.jacc.2016.01.063
M3 - Review article
C2 - 27081024
AN - SCOPUS:84963644389
SN - 0735-1097
VL - 67
SP - 1829
EP - 1845
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 15
ER -